None listed
Conditions
Interventions
Intervention1: sildenafil: 20 mg three times daily, for 12 weeks
Control Intervention1: placebo: identical placebo was given three times daily
Sponsors
self
Eligibility
Inclusion criteria
Inclusion criteria: Ambulatory patients having severe or very severe COPD according to GOLD (global initiative for chronic obstructive lung disease) classification were recruited in the study if they had: past history of smoking at least 20 pack years. They had pulmonary artery systolic pressure of more than 40 mmHg as measured by Doppler echocardiography
Exclusion criteria
Exclusion criteria: Patients were not included if they had: acute exacerbation of COPD in last month, history of bronchial asthma or more than 12% increase in FEV1(forced expiratory volume one second) with bronchodilator, history of primary cardiac disease or documented ischaemic heart disease, use of nitrates or other vasodilator throughout the study period, hemoglobin less than 12g/dl, any severe concomitant disease, evidence of pulmonary artery hypertension due to any other cause such as pulmonary thromboembolism, Human Immunodeficiency Virus, scleroderma, congenital heart disease etc. and de-compensated right or left heart failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| distance covered in six minute walk testTimepoint: at baseline, after 4 weeks and after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| NYHA class of dyspnoea sense of well being pulmonary artery pressureTimepoint: at baseline, after 4 weeks and after 12 weeks | — |
Countries
India
Contacts
Public Contactdr virendra singh
prof and head of pulmonary division; SMS medical college and hospital. jaipur
Outcome results
None listed